全文获取类型
收费全文 | 1325篇 |
免费 | 119篇 |
国内免费 | 22篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 107篇 |
妇产科学 | 7篇 |
基础医学 | 198篇 |
口腔科学 | 20篇 |
临床医学 | 192篇 |
内科学 | 216篇 |
皮肤病学 | 21篇 |
神经病学 | 54篇 |
特种医学 | 124篇 |
外科学 | 140篇 |
综合类 | 38篇 |
预防医学 | 153篇 |
眼科学 | 60篇 |
药学 | 75篇 |
肿瘤学 | 54篇 |
出版年
2021年 | 13篇 |
2019年 | 17篇 |
2018年 | 19篇 |
2017年 | 11篇 |
2016年 | 16篇 |
2015年 | 11篇 |
2014年 | 28篇 |
2013年 | 31篇 |
2012年 | 48篇 |
2011年 | 46篇 |
2010年 | 46篇 |
2009年 | 27篇 |
2008年 | 42篇 |
2007年 | 62篇 |
2006年 | 42篇 |
2005年 | 55篇 |
2004年 | 24篇 |
2003年 | 35篇 |
2002年 | 30篇 |
2001年 | 35篇 |
2000年 | 36篇 |
1999年 | 39篇 |
1998年 | 46篇 |
1997年 | 52篇 |
1996年 | 42篇 |
1995年 | 28篇 |
1994年 | 31篇 |
1993年 | 23篇 |
1992年 | 30篇 |
1991年 | 32篇 |
1990年 | 23篇 |
1989年 | 26篇 |
1988年 | 41篇 |
1987年 | 35篇 |
1986年 | 27篇 |
1985年 | 21篇 |
1984年 | 17篇 |
1983年 | 21篇 |
1982年 | 32篇 |
1981年 | 19篇 |
1980年 | 17篇 |
1979年 | 11篇 |
1978年 | 24篇 |
1977年 | 22篇 |
1976年 | 19篇 |
1975年 | 13篇 |
1974年 | 13篇 |
1972年 | 13篇 |
1971年 | 10篇 |
1970年 | 12篇 |
排序方式: 共有1466条查询结果,搜索用时 9 毫秒
41.
42.
Michael Lowe Lesley Murray Alok Tyagi George Gorrie Sarah Miller Krishna Dani the NHS Greater Glasgow Clyde Headache Service 《The journal of headache and pain》2022,23(1)
BackgroundCalcitonin gene-related peptide (CGRP) inhibitors have been developed as options for treatment of chronic and episodic migraine. We present our experience of the use of erenumab in a tertiary headache centre.MethodsThis was a prospective clinical audit of all patients commenced on erenumab following a locally agreed pathway and criteria over a consecutive period. Patients received monthly erenumab 140 mg for 3 months. Data were collected prospectively at baseline and 3 months follow up.ResultsOne hundred three patients were commenced on erenumab during the study period. Patients had tried a median of 7 previous prophylactics, including onabotulinum toxin A in 94%. At 3 months there was a reduction in median total (28 to 20, 29% reduction, p < 0.0001) and severe (15 to 5, 67% reduction, p < 0.0001) headache days. 39.8% of patients achieved at least a 30% reduction in total headache days; 61.8% of patients achieved at least a 50% reduction in severe headache days. Meeting either of these thresholds was considered a positive response, 68% of patients achieved this. Presence of daily headache pattern was negatively associated with response, (56% response vs. 90% without daily headache, p = 0.0003). There was no association between age, gender, presence of medication overuse or number of previously tried prophylactic treatments and response to erenumab. 43% of patients reported at least one adverse effect, most commonly constipation (26%); treatment was discontinued in 3 patients due to adverse effects.ConclusionsErenumab was an effective treatment for chronic migraine in this treatment resistant population over 3 months of follow up. Presence of daily headache predicted poorer response but there was still a significant positive response rate in this group. 相似文献
43.
44.
Russell E. Glasgow Robert A. Zeiss Manuel Barrera Peter M. Lewinsohn 《Journal of clinical psychology》1977,33(4):1049-1054
Two case reports illustrate the application of mnemonic techniques for the remediation of memory problems common to brain-damaged patients. A clinical paradigm for such work that includes general and specific assessment, laboratory evaluation of intervention strategies, and finally in-vivo application is described. 相似文献
45.
Klatskin tumors of the bile ducts: sonographic appearance 总被引:4,自引:0,他引:4
The authors present 3 cases of surgically proved Klatskin tumor diagnosed by ultrasound alone. Sonographic features of these tumors include (a) dilatation of the intrahepatic biliary ducts but not the extrahepatic duct, (b) non-union of the right and left hepatic ducts, and (c) small, solid masses at the hepatic hilus. Local spread to the liver may also be seen. If the pancreas appears normal and no primary tumor can be found, Klatskin tumor can be diagnosed with a high degree of accuracy. 相似文献
46.
Factors influencing women to undergo screening mammography 总被引:2,自引:0,他引:2
47.
Cellular immunity in host resistance to viral infections 总被引:27,自引:0,他引:27
L A Glasgow 《Archives of internal medicine》1970,126(1):125-134
48.
Factors that affect human hemopoiesis are produced by T-cell growth factor dependent and independent cultured T-cell leukemia-lymphoma cells 总被引:3,自引:0,他引:3
Some laboratory results and clinical situations suggest that human T cells may be important in the regulation of growth of hematopoietic cells. Since the discovery of T-cell growth factor (TCGF), systems are now available for the long-term specific in vitro propagation of mature normal or neoplastic human T cells, providing an opportunity to study the influence of T cells on hematopoiesis. Recently, 24 cell lines from patients with cutaneous T-cell lymphoma (CTCL) and T-cell acute lymphoblastic leukemia (T-ALL) were grown with TCGF and then assessed for release of humoral factors that affect hematopoiesis. Conditioned media (CM) from these cell lines were tested for erythroid burst- promoting activity (BPA) and granulocyte colony-stimulating activity (CSA). BPA was detected in CM from 3/6 cultures of T-ALL patients and 4/6 CTCL cultures. CSA was found in the CM from 6/8 cultures of T-ALL patients, 7/12 CTCL cultures, and 3/4 CTCL cell lines that become independent of exogenous TCGF for growth. The CSA from several of the neoplastic T-cell cultures stimulated high levels of eosinophil colonies, a possible source of the eosinophilia seen in these patients. The ability of continuously proliferating human T lymphocytes, which retain functional specificity and responsiveness to normal humoral regulation, to produce factors that directly or indirectly stimulate myeloid and erythroid colony formation lends further credence to the role of T lymphocytes in regulating hematopoiesis. 相似文献
49.
High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy 总被引:2,自引:1,他引:2
Brown RA; Herzig RH; Wolff SN; Frei-Lahr D; Pineiro L; Bolwell BJ; Lowder JN; Harden EA; Hande KR; Herzig GP 《Blood》1990,76(3):473-479
Seventy-five patients with resistant acute leukemia or lymphoma received high-dose cyclophosphamide and etoposide to explore the activity of this combination in resistant hematologic malignancies, and to determine the maximum doses of these drugs that can be combined without bone marrow transplantation. Etoposide was administered over 29 to 69 hours by continuous infusion corresponding to total doses of 1.8 g/m2 to 4.8 g/m2. Cyclophosphamide, 50 mg/kg/d, was administered on 3 or 4 consecutive days total 150 to 200 mg/kg ideal body weight). At all dose levels myelosuppression was severe but reversible. Mucosal toxicity was dose-limiting with the maximum tolerated dose level combining etoposide 4.2 g/m2 with cyclophosphamide 200 mg/kg. Continuous etoposide infusion produced stable plasma levels that were lower than would be achieved after administration by short intravenous infusion, and this could explain our ability to escalate etoposide above the previously reported maximum tolerated dose. There were 28 complete (35%) and 12 partial (16%) responses. Median duration of complete response (CR) was 3.5 months (range 1.1 to 20+). Seventeen of 40 patients (42%) with acute myelogenous leukemia (AML) achieved CR, including 6 of 20 (30%) with high-dose cytosine arabinoside resistance. We conclude that bone marrow transplantation is not required after maximum tolerated doses of etoposide and cyclophosphamide. This regimen is active in resistant hematologic neoplasms, and the occurrence of CR in patients with high-dose cytosine arabinoside-resistant AML indicates a lack of complete cross-resistance between these regimens. 相似文献
50.
Monitoring of streptokinase resistance titre in acute myocardial infarction patients up to 30 months after giving streptokinase or anistreplase and related studies to measure specific antistreptokinase IgG 下载免费PDF全文
R Fears H Ferres E Glasgow R Standring K J Hogg J D Gemmill J M A Burns A P Rae F G Dunn W S Hillis 《Heart (British Cardiac Society)》1992,68(2):167-170
Objective—To examine the induction of antistreptokinase antibodies after giving streptokinase or anistreplase to patients with acute myocardial infarction.Design—Patients were randomly allocated to receive either 1·5 × 106 IU, streptokinase or 30U anistreplase in a double blind study. Blood samples were collected immediately before treatment and subsequently at intervals up to 30 months; plasma samples were assayed for streptokinase resistance titre (functional assay) and streptokinase binding by IgG (microradioimmunoassay).Setting—Cardiology department in a general hospital.Patients—128 consecutive eligible patients. Samples were collected for up to one year according to a prospective design: a subsection of 47 patients was selected for intensive study over the first 14 days. After one year, all available patients (67) were sampled on one further occasion.Results—Antibody responses to streptokinase and anistreplase were similar. Streptokinase resistance titres exceeded pretreatment concentrations five days after dosing, and values peaked at 14 days. By 12 months after dosing, 92% of resistance titres (n = 84) had returned to within the pretreatment range. Antistreptokinase IgG concentrations also exceeded baseline concentrations within five days and peaked at 14 days. Half of the individual values had returned to within the pretreatment range by 12 months (n = 84) and 89% by 30 months (n = 18).Conclusion—Although we cannot be sure of the clinical significance, because of the increased likelihood of resistance due to antistreptokinase antibody, streptokinase and anistreplase may not be effective if administered more than five days after an earlier dose of streptokinase or anistreplase, particularly between five days and 12 months, and increased antistreptokinase antibody may increase the risk of allergic-type reactions. 相似文献